DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous 
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Financial Guidance 
2021-06-29 / 01:11 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Vivoryon Therapeutics Provides Update on Financial Guidance 
Halle (Saale) / Munich, Germany, June 29, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) 
(Vivoryon), a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines, 
today announced an update on its financial guidance. According to current estimates, the Company expects the recently 
signed regional licensing agreement with Simcere Pharmaceutical Group Ltd. to have an impact on Vivoryon's previously 
communicated cash-reach of Q3 2022, which is anticipated to be extended for at least three quarters until Q2 2023. A 
detailed update on anticipated working capital requirements and resulting timelines will be given in the context of the 
Company's regular filings. 
 
Vivoryon and Simcere have entered into a strategic regional licensing partnership to develop and commercialize 
medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease (AD) in Greater 
China. Under the terms of the agreement, Vivoryon will receive an undisclosed upfront payment and will also be eligible 
for payments upon achievement of certain development and sales milestones, with all components amounting to a total of 
over USUSD565 M. In addition, Vivoryon will receive double-digit royalties on sales. Further financial details were not 
disclosed. 
 
### 
 
About Vivoryon Therapeutics N.V. 
Vivoryon is a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines. 
Driven by our passion for ground-breaking science and innovation, we strive to change the live of medically underserved 
patients suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational 
modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease 
settings before they cause irreversible damage. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical 
development to treat Alzheimer's disease, we have established a solid pipeline of orally available small molecule 
inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com 
 
Vivoryon Forward Looking Statements 
Information set forth in this press release contains forward-looking statements, which involve a number of risks and 
uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics N.V. as 
of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject 
to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to 
differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or 
undertaking to release publicly any updates or revisions to any such statements to reflect any change in our 
expectations or any change in events, conditions or circumstances on which any such statement is based. 
For more information, please contact: 
Vivoryon Therapeutics N.V. 
Investor Contact 
Dr. Manuela Bader, Director IR & Communication 
Tel: +49 (0)345 555 99 30 
Email: IR@vivoryon.com 
Media Contact 
Trophic Communications 
Stephanie May / Sophia Hergenhan 
Tel: +49 (0)171 185 5682 
Email: vivoryon@trophic.eu 
=---------------------------------------------------------------------------------------------------------------------- 
2021-06-29 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Vivoryon Therapeutics N.V. 
              Weinbergweg 22 
              06120 Halle/Saale 
              Germany 
Phone:        +49 (0)345 555 9900 
Fax:          +49 (0)345 555 9901 
E-mail:       contact@vivoryon.com 
Internet:     www.vivoryon.com 
ISIN:         NL00150002Q7 
WKN:          A2QJV6 
Listed:       Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam 
EQS News ID:  1212936 
 
End of News   DGAP News Service 
=------------

1212936 2021-06-29


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1212936&application_name=news

(END) Dow Jones Newswires

June 28, 2021 19:13 ET (23:13 GMT)